These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 32759570)

  • 1. [SLAM family proteins as therapeutic targets in multiple myeloma].
    Tamura H; Ishibashi M; Takahashi H; Inokuchi K
    Rinsho Ketsueki; 2020; 61(7):818-826. PubMed ID: 32759570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SLAMF3-Mediated Signaling via ERK Pathway Activation Promotes Aggressive Phenotypic Behaviors in Multiple Myeloma.
    Ishibashi M; Takahashi R; Tsubota A; Sasaki M; Handa H; Imai Y; Tanaka N; Tsukune Y; Tanosaki S; Ito S; Asayama T; Sunakawa M; Kaito Y; Kuribayashi-Hamada Y; Onodera A; Moriya K; Komatsu N; Tanaka J; Odajima T; Sugimori H; Inokuchi K; Tamura H
    Mol Cancer Res; 2020 Apr; 18(4):632-643. PubMed ID: 31974290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Functions of Signaling Lymphocytic Activation Molecule Family Molecules in Multiple Myeloma.
    Ishibashi M; Morita R; Tamura H
    Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33451089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7.
    Kikuchi J; Hori M; Iha H; Toyama-Sorimachi N; Hagiwara S; Kuroda Y; Koyama D; Izumi T; Yasui H; Suzuki A; Furukawa Y
    Leukemia; 2020 Jan; 34(1):180-195. PubMed ID: 31358854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma.
    Campbell KS; Cohen AD; Pazina T
    Front Immunol; 2018; 9():2551. PubMed ID: 30455698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical impact of serum soluble SLAMF7 in multiple myeloma.
    Ishibashi M; Soeda S; Sasaki M; Handa H; Imai Y; Tanaka N; Tanosaki S; Ito S; Odajima T; Sugimori H; Asayama T; Sunakawa M; Kaito Y; Kinoshita R; Kuribayashi Y; Onodera A; Moriya K; Tanaka J; Tsukune Y; Komatsu N; Inokuchi K; Tamura H
    Oncotarget; 2018 Oct; 9(78):34784-34793. PubMed ID: 30410677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression analysis of two SLAM family receptors, SLAMF2 and SLAMF7, in patients with multiple myeloma.
    Ashour R; Ri M; Aly SS; Yoshida T; Tachita T; Kanamori T; Aoki S; Kinoshita S; Narita T; Totani H; Masaki A; Ito A; Kusumoto S; Komatsu H; Mansour S; Elsaied AA; Iida S
    Int J Hematol; 2019 Jul; 110(1):69-76. PubMed ID: 31115879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment.
    Magen H; Muchtar E
    Ther Adv Hematol; 2016 Aug; 7(4):187-95. PubMed ID: 27493709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy.
    Zamagni E; Tacchetti P; Pantani L; Cavo M
    Expert Rev Hematol; 2018 May; 11(5):423-435. PubMed ID: 29582696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SLAMF7 as a Promising Immunotherapeutic Target in Multiple Myeloma Treatments.
    Chu E; Wu J; Kang SS; Kang Y
    Curr Oncol; 2023 Aug; 30(9):7891-7903. PubMed ID: 37754488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elotuzumab as a novel anti-myeloma immunotherapy.
    Radhakrishnan SV; Bhardwaj N; Steinbach M; Weidner J; Luetkens T; Atanackovic D
    Hum Vaccin Immunother; 2017 Aug; 13(8):1751-1757. PubMed ID: 28604269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Signaling Lymphocytic Activation Molecule Family Receptor Homologs in New World Monkey Cytomegaloviruses.
    Pérez-Carmona N; Farré D; Martínez-Vicente P; Terhorst C; Engel P; Angulo A
    J Virol; 2015 Nov; 89(22):11323-36. PubMed ID: 26339044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and Validation of Electrochemiluminescence Assays to Measure Free and Total sSLAMF7 in Human Serum in the Absence and Presence of Elotuzumab.
    Postelnek J; Neely RJ; Robbins MD; Gleason CR; Peterson JE; Piccoli SP
    AAPS J; 2016 Jul; 18(4):989-99. PubMed ID: 27116021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma.
    Pazina T; James AM; Colby KB; Yang Y; Gale A; Jhatakia A; Kearney AY; Graziano RF; Bezman NA; Robbins MD; Cohen AD; Campbell KS
    Cancer Immunol Res; 2019 Oct; 7(10):1633-1646. PubMed ID: 31431433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical potential of SLAMF7 antibodies - focus on elotuzumab in multiple myeloma.
    Friend R; Bhutani M; Voorhees PM; Usmani SZ
    Drug Des Devel Ther; 2017; 11():893-900. PubMed ID: 28356715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on elotuzumab for the treatment of relapsed/refractory multiple myeloma: patients' selection and perspective.
    Trudel S; Moreau P; Touzeau C
    Onco Targets Ther; 2019; 12():5813-5822. PubMed ID: 31410026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab.
    Chen WC; Kanate AS; Craig M; Petros WP; Hazlehurst LA
    Cancer Manag Res; 2017; 9():307-314. PubMed ID: 28744161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of surface molecule CD229 in Multiple Myeloma.
    Olson M; Radhakrishnan SV; Luetkens T; Atanackovic D
    Clin Immunol; 2019 Jul; 204():69-73. PubMed ID: 30326256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review discussing elotuzumab and its use in the second-line plus treatment of multiple myeloma.
    Offidani M; Corvatta L
    Future Oncol; 2018 Feb; 14(4):319-329. PubMed ID: 29091475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.